An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

Europe and Japan.” But months after the FDA's approval of the use of donanemab in the US, they are yet to decide if it will be suitable for use in the UK. In July, the FDA granted approval for ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

Eli Lilly's Kisunla has been approved in Japan for early symptomatic Alzheimer's disease, following its US approval in July ...

Indianapolis: Eli Lilly and Company's has announced that the Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai ...

In Japan, the business community sees election-year politics at play. President Joe Biden is preparing to formally block the proposed takeover of U.S. Steel by Nippon Steel, two people familiar ...

Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...

Japan's health ministry has officially approved the domestic production and sale of a new drug for Alzheimer's disease.